A Strong Showing in MIS
The MIS roller coaster is heading up again. Just a couple of years ago, the slow acceptance of MIS procedures by general surgeons beyond laparoscopic cholecystectomy-in hernia repair, for example, or appendectomy-had everyone wondering just how muchpromise the MIS market holds.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.